Recombinant Human APBA1 protein, GST-tagged
Cat.No. : | APBA1-666H |
Product Overview : | Human APBA1 full-length ORF ( AAI56048.1, 1 a.a. - 837 a.a.) recombinant protein with GST-tag at N-terminal. |
- Specification
- Gene Information
- Related Products
- Download
Description : | The protein encoded by this gene is a member of the X11 protein family. It is a neuronal adapter protein that interacts with the Alzheimer's disease amyloid precursor protein (APP). It stabilizes APP and inhibits production of proteolytic APP fragments including the A beta peptide that is deposited in the brains of Alzheimer's disease patients. This gene product is believed to be involved in signal transduction processes. It is also regarded as a putative vesicular trafficking protein in the brain that can form a complex with the potential to couple synaptic vesicle exocytosis to neuronal cell adhesion. [provided by RefSeq, Jul 2008] |
Source : | Wheat Germ |
Species : | Human |
Tag : | GST |
Molecular Mass : | 92.1 kDa |
AA Sequence : | MNHLEGSAEVEVTDEAAGGEVNESV EADLEHPEVEEEQQQPPQQQHYVGR HQRGRALEDLRAQLGQEEEERGECL ARSASTESGFHNHTDTAEGDVIAAA RDGYDAERAQDPEDESAYAVQYRPE AEEYTEQAEAEHAEATHRRALPNHL HFHSLEHEEAMNAAYSGYVYTHRLF HRGEDEPYSEPYADYGGLQEHVYEE IGDAPELDARDGLRLYEQERDEAAA YRQEALGARLHHYDERSDGESDSPE KEAEFAPYPRMDSYEQEEDIDQIVA EVKQSMSSQSLDKAAEDMPEAEQDL ERPPTPAGGRPDSPGLQAPAGQQRA VGPAGGGEAGQRYSKEKRDAISLAI KDIKEAIEEVKTRTIRSPYTPDEPK EPIWVMRQDISPTRDCDDQRPMDGD SPSPGSSSPLGAESSSTSLHPSDPV EASTNKESRKSLASFPTYVEVPGPC DPEDLIDGIIFAANYLGSTQLLSDK TPSKNVRMMQAQEAVSRIKMAQKLA KSRKKAPEGESQPMTEVDLFISTQR IKVLNADTQETMMDHPLRTISYIAD IGNIVVLMARRRMPRSNSQENVEAS HPSQDGKRQYKMICHVFESEDAQLI AQSIGQAFSVAYQEFLRANGINPED LSQKEYSDLLNTQDMYNDDLIHFSK SENCKDVFIEKQKGEILGVVIVESG WGSILPTVIIANMMHGGPAEKSGKL NIGDQIMSINGTSLVGLPLSTCQSI IKGLKNQSRVKLNIVRCPPVTTVLI RRPDLRYQLGFSVQNGIICSLMRGG IAERGGVRVGHRIIEINGQSVVATP HEKIVHILSNAVGEIHMKTMPAAMY RLLTAQEQPVYI |
Applications : | Enzyme-linked Immunoabsorbent Assay; Western Blot (Recombinant protein); Antibody Production; Protein Array |
Notes : | Best use within three months from the date of receipt of this protein. |
Storage : | Store at -80 centigrade. Aliquot to avoid repeated freezing and thawing. |
Storage Buffer : | 50 mM Tris-HCI, 10 mM reduced Glutathione, pH=8.0 in the elution buffer. |
Gene Name : | APBA1 amyloid beta (A4) precursor protein-binding, family A, member 1 [ Homo sapiens ] |
Official Symbol : | APBA1 |
Synonyms : | APBA1; amyloid beta (A4) precursor protein-binding, family A, member 1; MINT1; amyloid beta A4 precursor protein-binding family A member 1; D9S411E; X11; mint-1; adapter protein X11alpha; adaptor protein X11alpha; neuron-specific X11 protein; neuronal munc18-1-interacting protein 1; phosphotyrosine-binding/-interacting domain (PTB)-bearing protein; amyloid beta (A4) precursor protein-binding, family A, member 1 (X11); X11A; LIN10; X11ALPHA; |
Gene ID : | 320 |
mRNA Refseq : | NM_001163 |
Protein Refseq : | NP_001154 |
MIM : | 602414 |
UniProt ID : | Q02410 |
Products Types
◆ Recombinant Protein | ||
APBA1-363R | Recombinant Rat APBA1 Protein, His (Fc)-Avi-tagged | +Inquiry |
APBA1-707R | Recombinant Rat APBA1 Protein | +Inquiry |
Apba1-3434R | Recombinant Rat Apba1, His-tagged | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (20)
Ask a questionIn scientific research, recombinant APBA1 protein can be used to study the function, interaction and regulatory mechanism of APBA1, which is conducive to in-depth understanding of the pathogenesis of related diseases.
The recombinant APBA1 protein is not usually used to diagnose diseases, but for treatment and research.
The dosage needs to be determined according to the specific disease type, the patient's condition and the purpose for which the APBA1 is used. It is best to adjust the dosage under the guidance of a doctor.
The development of oral formulations is a challenging goal, but it is possible to achieve oral administration of APBA1 through technological advances in the future.
The use of APBA1 needs to be determined based on the specific disease and treatment regimen, and may require long-term use or intermittent use.
There are currently no APBA1 products that have passed clinical trials and been approved.
The manufacturing process of APBA1 requires strict quality standards to ensure the safety and effectiveness of the product.
At present, there are no reports of resistance of APBA1 , but the existence of individual differences cannot be ruled out.
When using APBA1 , it is necessary to pay attention to the interaction with other drugs, and to use the combination under the guidance of a doctor.
The time for the therapeutic effect of APBA1 varies from person to person, and the specific effect needs to be judged according to the patient's condition and medication.
There have been no clear reports of side effects of APBA1 , but it is still necessary to closely monitor the patient's condition and physiological indicators during use.
The function and efficacy of APBA1 may be different in patients from different regions, and further studies are needed to determine it.
The age limit for the use of APBA1 needs to be determined according to the specific disease and medication situation, and it is best to use under the guidance of a doctor.
Future studies may explore the development of an APBA1 drug for export, but further research and clinical trials are currently needed.
APBA1 should be stored in a dry, cool place and avoid exposure to direct sunlight.
APBA1 is a recombinant synthetic protein that has a similar function to the protein encoded by the APBA1 gene.
The recombinant APBA1 protein can be used to treat diseases associated with APBA1, such as neurodegenerative diseases and cognitive disorders.
In the course of the treatment of APBA1 , it is generally necessary to regularly monitor the relevant disease and physiological indicators, and adjust the dose and treatment plan.
APBA1 is still in the research stage, and more clinical data and research evidence are needed to determine whether it can replace traditional treatment methods.
At present, the treatment for APBA1-related diseases is still in the research stage, and the success rate needs to be further explored and verified.
Customer Reviews (4)
Write a reviewProduction process of APBA1 focuses on sustainable development, and maximizes the use of energy and resources by optimizing the production process and equipment, which is very environmentally friendly.
Due to the short half-life and high clearance of recombinant protein, it can better adapt to the treatment needs of patients of different ages and physiological states.
The stability of the experiment with this protein is very good, which greatly reduces the error of the experiment and improves the accuracy of the experiment.
Stability and repeatability of APBA1 is truly impressive! Regardless of the environment, it can maintain stable performance, making scientific research results more reliable.
Ask a Question for All APBA1 Products
Required fields are marked with *
My Review for All APBA1 Products
Required fields are marked with *
Inquiry Basket